Our Team

Florence Séjourné - Chief Executive Officer

fs.jpgFlorence Séjourné joined Da Volterra as CEO in the summer of 2008. She graduated from the “Ecole Nationale Supérieure des Mines de Paris” in 1994 with a major in biotechnology, and from the University of Illinois at Chicago with a Master of Pharmaceutical Sciences in 1996. She led the biotech department of Eurasanté one of the first French bioincubators and assisting start-up entrepreneurs. Then co-founded Genfit, one of the leading public European biotech companies in the cardiovascular and metabolic fields, where she was Chief Operating Officer, VP Business Development, Alliance manager and member of the Board from 1999 to 2008.
Florence Séjourné therefore brings to Da Volterra the experience of a successful entrepreneurial adventure, including her capacity to set up and lead a highly professional R&D organization, to raise private and public funds, and to structure and negotiate deals with Pharmaceutical and Biotech Companies in a highly competitive international environment.  In addition, Florence Séjourné is the president of the BEAM Alliance.


Jean de Gunzburg - PhD, Chief Scientific Officer

Jean de Gunzburg Jean de Gunzburg graduated from “Ecole Agronomique de Paris” before becoming a molecular and cell biologist who after a highly successful academic carrier decided to devote his experience and know-how to the development of Da Volterra.
After obtaining his Ph.D. in 1985 from the University of Paris 7 for work performed at the Institut Pasteur in Paris, Jean continued his training by a postdoctoral stay at the Whitehead Institute for Biomedical Research (Cambridge). He became in 1988 Research Director at the CNRS and headed the Laboratory for Signal Transduction and Oncogenesis of Inserm at the Institut Curie in Paris until mid 2005. He has published over 70 articles in international journals in fields ranging from Biochemistry and Molecular Biology to Cell biology. Jean de Gunzburg, as a seasoned scientist, brings to Da Volterra his wide expertise for conducting R&D programs, understanding finely at the molecular level diseases as well as drugs mode of action, developing adequate in vitro assays to model in vivo situations, optimizing both chemical and molecular analytical tools and biomarkers, and establishing in vivo proof of concept studies. Jean heads the R&D efforts of Da Volterra in close synergy with Antoine Andremont and Annie Ducher.


Annie DucherAnnie Ducher joined Da Volterra as Chief Medical Officer in the summer of 2010. Annie Ducher is a graduate MD from University of Paris V, and MS in "Methodology and Assessment of the Development of Drugs" with Pr Alexandre (Chairman of French & European Drug Committee). Her expertise field is the clinical development of antimicrobials and the strategy of registration. Annie started her career at the French Regulatory Agency (AFSSAPS), as Manager of anti-infective working group. She then had various responsibilities as consultant or senior director in anti-infective development for or in several companies (Centocor, Aventis, SB, GSK, Novexel) in France and in the UK. In total, she had the opportunity to oversee at least 10 clinical programs in all development phases of antimicrobials and sepsis products. From 1989 to 2005, Annie continued to be a part-time Hospital practitioner in the Infectious and Tropical Diseases Unit of Pr Rozenbaum in Paris and has therefore remained deeply connected to patient care as well as drug development.

Karine Bertrand - Chief  technical Officer

Karine BertrandKarine Bertrand graduated from ESPCI ParisTech (‘Ecole Supérieure de Physique et Chimie Industrielles’) before obtaining her Ph.D in medicinal and organic chemistry from the University of Lille. She started her career at UCB before joining the leading European biopharmaceutical company, Genfit, from its inception. She has held several management positions as Director R&D Chemistry, CMC Development, Strategic Planning and Program Management, and EVP, Corporate Development. With her broad understanding of the healthcare industry environment, Karine Bertrand brings to Da Volterra her high operational and technical expertise in research and development of therapeutic products, including her skills in discovering, developing and executing product decisions, and the definition and implementation of product roadmaps and go-to-market strategies.

Stéphane Postic - Chief Financial Officer

sp_0.jpgStéphane Postic, business graduate from the EM Lyon University, has held several financial management positions in large international distribution companies such as Pinault-Printemps-Redoute and Carrefour. He has been responsible for financial reporting and management of several business units in France and in the UK and has gained solid experience in profit centre management. Since April 2002, he had supervised the administrative and financial teams at Genfit and managed the Financial and Business Control, General Administration, Human Resources and Corporate Reporting functions, in close collaboration with the CEO and COO. In charge of the IPO of Genfit in 2006, he gained a strong experience in biotech financing. Working part-time as CFO of Da Volterra, Stephane brings both his high technical expertise in finance and corporate administration and his strategic advice to the CEO.

Pierre-Alain Bandinelli - Chief Business OFFICER

pab.jpgPierre-Alain Bandinelli joined Da Volterra’s team in late 2009 after graduating from the “Ecole Polytechnique” and “Ecole Nationale Supérieure des Mines de Paris ” with majors in biology and biotechnology management. He previously worked in Dr.Elisseeff’s team in Johns Hopkins (Baltimore, USA) on innovative tissue engineering techniques to heal cartilage defects. He is today Chief Business Officer at Da Volterra, and takes an active part in identifying and setting up the company’s partnerships, grant consortia, and coordinates IP portfolio management, market intelligence and strategic analysis at Da Volterra.

The team of Da Volterrateam.jpg